Telix Pharmaceuticals Limited filed a Form 6-K on April 13, 2026, announcing a radiopharma collaboration with Regeneron, as detailed in the attached press release.
Key takeaways
Telix Pharmaceuticals Limited announced a radiopharma collaboration with Regeneron on April 13, 2026.
The announcement was filed with the Australian Securities Exchange and attached as Exhibit 99.1 to this Form 6-K.
The information in this Form 6-K is incorporated by reference into the company's Registration Statements on Form F-3ASR and Form S-8.
The press release contains commentary in the third, fourth, and fifth paragraphs on page 1 that is not incorporated by reference.